Cargando…

Gut dysbiosis is associated with poorer long-term prognosis in cirrhosis

BACKGROUND: Gut dysbiosis is common in cirrhosis. AIM: To study the influence of gut dysbiosis on prognosis in cirrhosis. METHODS: The case-control study included 48 in-patients with cirrhosis and 21 healthy controls. Stool microbiome was assessed using 16S ribosomal ribonucleic acid gene sequencing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maslennikov, Roman, Ivashkin, Vladimir, Efremova, Irina, Alieva, Aliya, Kashuh, Ekaterina, Tsvetaeva, Ekaterina, Poluektova, Elena, Shirokova, Elena, Ivashkin, Konstantin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Case Control Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173342/ https://www.ncbi.nlm.nih.gov/pubmed/34131470 http://dx.doi.org/10.4254/wjh.v13.i5.557

Ejemplares similares

Effect of probiotics on hemodynamic changes and complications associated with cirrhosis: A pilot randomized controlled trial
por: Maslennikov, Roman, et al.
Publicado: (2022)

Small Intestinal Bacterial Overgrowth Is Associated with Poor Prognosis in Cirrhosis
por: Efremova, Irina, et al.
Publicado: (2023)

Gut-liver axis in cirrhosis: Are hemodynamic changes a missing link?
por: Maslennikov, Roman, et al.
Publicado: (2021)

Gut dysbiosis and body composition in cirrhosis
por: Maslennikov, Roman, et al.
Publicado: (2022)

Gut Dysbiosis and Hemodynamic Changes as Links of the Pathogenesis of Complications of Cirrhosis
por: Efremova, Irina, et al.
Publicado: (2023)

Gut dysbiosis and small intestinal bacterial overgrowth as independent forms of gut microbiota disorders in cirrhosis
por: Maslennikov, Roman, et al.
Publicado: (2022)

Probiotics in hepatology: An update
por: Maslennikov, Roman, et al.
Publicado: (2021)

Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota
por: Maslennikov, Roman, et al.
Publicado: (2023)

Probiotic Saccharomyces boulardii in the Treatment of Small Intestinal Bacterial Overgrowth in Decompensated Cirrhosis
por: Maslennikov, Roman, et al.
Publicado: (2022)

Immune disorders and rheumatologic manifestations of viral hepatitis
por: Maslennikov, Roman, et al.
Publicado: (2021)

Epidemiology of small intestinal bacterial overgrowth
por: Efremova, Irina, et al.
Publicado: (2023)

NT-proBNP as a biomarker for hyperdynamic circulation in decompensated cirrhosis
por: Maslennikov, Roman, et al.
Publicado: (2018)

Differences in Fecal Short-Chain Fatty Acids between Alcoholic Fatty Liver-Induced Cirrhosis and Non-alcoholic (Metabolic-Associated) Fatty Liver-Induced Cirrhosis
por: Cao, Xinlu, et al.
Publicado: (2023)

Clostridioides difficile co-infection in patients with COVID-19
por: Maslennikov, Roman, et al.
Publicado: (2022)

Impact of vaccination against the novel coronavirus infection (COVID-19) with Sputnik V on mortality during the delta variant surge
por: Dmitrieva, Ksenia, et al.
Publicado: (2023)

Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis
por: Maslennikov, Roman, et al.
Publicado: (2023)

Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations?
por: Mamieva, Zarina, et al.
Publicado: (2022)

Dos ataques de diarrea consecutivos en 15 pacientes de COVID-19: uno asociado con antibióticos posterior a uno viral
por: Maslennikov, R., et al.
Publicado: (2022)

Two consecutive attacks of diarrhea in 15 COVID-19 patients: An antibiotic-associated one following the viral one()
por: Maslennikov, R., et al.
Publicado: (2022)

Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19)
por: Maslennikov, Roman, et al.
Publicado: (2021)

Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19
por: Maslennikov, Roman, et al.
Publicado: (2021)

Eubiotic effect of rifaximin is associated with decreasing abdominal pain in symptomatic uncomplicated diverticular disease: results from an observational cohort study
por: Ivashkin, Vladimir, et al.
Publicado: (2023)

Efficacy and safety of COVID-19 vaccination in patients with cirrhosis
por: Ivashkin, Vladimir, et al.
Publicado: (2022)

Effect of Rebamipide on the Intestinal Barrier, Gut Microbiota Structure and Function, and Symptom Severity Associated with Irritable Bowel Syndrome and Functional Dyspepsia Overlap: A Randomized Controlled Trial
por: Kovaleva, Aleksandra, et al.
Publicado: (2023)

Efficacy of a Probiotic Consisting of Lacticaseibacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911, and Bifidobacterium longum subsp. longum PDV 2301 in the Treatment of Hospitalized Patients with COVID-19: a Randomized Controlled Trial
por: Ivashkin, Vladimir, et al.
Publicado: (2021)

Early viral versus late antibiotic-associated diarrhea in novel coronavirus infection
por: Maslennikov, Roman, et al.
Publicado: (2021)

Pathogenetic approach to the treatment of functional disorders of the gastrointestinal tract and their intersection: results of the Russian observation retrospective program COMFORT
por: Ivashkin, Vladimir T., et al.
Publicado: (2019)

Correlation of Objective Endpoints and Subjective Patient-Reported Outcomes in NAFLD Treatment with Essential Phospholipids: Real-World Data Based on Pooled Analysis of Observational Studies
por: Ivashkin, Vladimir T., et al.
Publicado: (2021)

Disruption of the pro-inflammatory, anti-inflammatory cytokines and tight junction proteins expression, associated with changes of the composition of the gut microbiota in patients with irritable bowel syndrome
por: Ivashkin, V., et al.
Publicado: (2021)

Intermittent hypoxia is involved in gut microbial dysbiosis in type 2 diabetes mellitus and obstructive sleep apnea-hypopnea syndrome
por: Tang, Sha-Sha, et al.
Publicado: (2022)

A Metabolic Activity Recovery of the Intestinal Microbiota in the Patients with Bronchial Asthma
por: Ozimek, Mariusz, et al.
Publicado: (2022)

Promising Markers of Inflammatory and Gut Dysbiosis in Patients with Post-COVID-19 Syndrome
por: Sorokina, Ekaterina, et al.
Publicado: (2023)

A Recent Ten-Year Perspective: Bile Acid Metabolism and Signaling
por: Shulpekova, Yulia, et al.
Publicado: (2022)

Risk factors for poorer health literacy in patients with liver cirrhosis
por: Kaps, Leonard, et al.
Publicado: (2021)

The effects of Levilactobacillus brevis on the physiological parameters and gut microbiota composition of rats subjected to desynchronosis
por: Olekhnovich, Evgenii I., et al.
Publicado: (2021)

Oral Dysbiosis in Pancreatic Cancer and Liver Cirrhosis: A Review of the Literature
por: Mohammed, Hiba, et al.
Publicado: (2018)

Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis
por: Nishikawa, Hiroki, et al.
Publicado: (2020)

Liver cirrhosis leads to poorer survival in patients with end-stage renal disease
por: Kim, Ae Jin, et al.
Publicado: (2016)

Risk of progression of Barrett's esophagus in patients with cirrhosis
por: Apfel, Tehilla, et al.
Publicado: (2017)

Mechanisms underlying dual effects of serotonin during development of Helisoma trivolvis (Mollusca)
por: Glebov, Konstantin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ok2nf03bgpgij04lrocts13juj